A pathway known for its role in asthma and allergic inflammation may also help aggressive cancers evade immune attack by exploiting the inflammatory receptor CysLTR1 to reshape white blood cells into immune-suppressing cells that interfere with cancer immunotherapy. The post FDA-Approved Asthma Drug Boosts Efficacy of Immunotherapy in Aggressive Cancers appeared first on Inside Precision Medicine .